Clinical implications of CIP2A protein expression in breast cancer

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Yu, Guangzhe ^a   Liu, Guohong ^b   Dong, Juan ^a   Jin, Yingyu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Chemotherapeutic sensitivity; CIP2A protein; Prognosis

Indexed keywords

CIP2A PROTEIN; PROTEIN; UNCLASSIFIED DRUG; AUTOANTIGEN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; DISTANT METASTASIS; FEMALE; GENETIC CORRELATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; UNIVARIATE ANALYSIS; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AUTOANTIGENS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84874643751     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0524-9     Document Type: Article

References (15)

1. Dowling EC, Klabunde C, Patnick J, Ballard-Barbash R. For the International Cancer Screening Network (ICSN): breast and cervical cancer screening programme implementation in 16 countries. J Med Screen. 2010;17:139-46.
2. Gaffan J, Dacre J, Jones A. Educating undergraduate medical students about oncology: a literature review. J Clin Oncol. 2006;24(12):1932-9.
3. Xu D, Xu H, Ren Y, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS ONE. 2012;7(10):e46670.
4. Liu Caigang, Chen Bo, Zhu Jun, et al. Clinical implications for nestin protein expression in breast cancer. Cancer Sci. 2010;101(3):815-9.
5. Kikuno R, Nagase T, Ishikawa K, et al. Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1999;6(3):197-205.
6. Junttila MR, Puustinen P, Niemelä M, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130(1):51-62.
7. Böckelman C, Koskensalo S, Hagström J, et al. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther. 2012;13(5):289-95.
8. Vaarala MH, Väisänen MR, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 2010;29:136.
9. Xu P, Xu XL, Huang Q, Zhang ZH, Zhang YB. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med Oncol. 2012;29(3):1643-7.
10. Côme C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15(16):5092-100.
11. Niemelä M, Kauko O, Sihto H, et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene. 2012;31(39):4266-78.
12. Huang LP, Savoly D, Sidi AA, et al. CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med. 2012;1(1):76-81.
13. Xue Y, Wu G, Wang X, et al. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Med Oncol. 2013;30(1):406.
14. Yu HC, Chen HJ, Chang YL, et al. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol. 2013;85(3):356-66.
15. Tseng LM, Liu CY, Chang KC, et al. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 2012;14(2):R68.